FC PROTEIN AND GLYCOENGINEERED ANTIBODIES MARKET ANALYSIS

Fc Protein and Glycoengineered Antibodies Market, by Drug (Approved Drugs (Obinutuzumab (Gazyva), Mogamulizumab (Poteligeo), Atezolizumab (Tecentriq), and Durvalumab (Imfinzi)) and Pipeline drugs (Ublituximab and Others)), by Application (Oncology, Autoimmune Disease, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI2626
Formats :
Excel and PDF
Industry : Pharmaceutical

Fc Protein And Glycoengineered Antibodies MarketSize and Trends

Global Fc Protein and Glycoengineered Antibodies Market Drivers

Key players in the market are focusing on research and development activities and receiving approvals from regulatory bodies, which are expected to boost the global Fc protein and glycoengineered antibodies market growth over the forecast period.

For instance, in 2016, Genentech Inc. received approval from the U.S. Food and drug Administration (U.S. FDA) for Tecentriq (Atezolizumab). It is being used for the treatment of urothelial carcinoma. In March 2019, Tecentriq received its second approval from the U.S. FDA for the treatment of small lung cancer. Furthermore, in November 2017, TG Therapeutics, Inc. began its clinical trial of Ublituximab for the treatment of multiple sclerosis. It is currently in third phase of its clinical trial. Factors such as increasing product approvals and robust pipeline are expected to drive the global fc protein and glycoengineered antibodies market growth.

Increasing prevalence of diseases such as cancer is expected to propel the global Fc protein and glycoengineered antibodies market growth. According to the World Health Organization (WHO), cancer is considered as the second most leading cause of death worldwide, and, in 2018, around 9.6 million people died worldwide due to cancer. Hence, glycoengineered antibodies can be developed for the treatment of cancer and thus, this factor is expected to drive growth of the global fc protein and glycoengineered antibodies market over the forecast period.